Boston Scientific vs Novo Nordisk (BSX vs NVO)
Boston Scientific (BSX) vs Novo Nordisk (NVO) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.
Boston Scientific (BSX) and Novo Nordisk (NVO) compete in healthcare and pharma. Here are Boston Scientific and Novo Nordisk side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Boston Scientific or Novo Nordisk.
Boston Scientific vs Novo Nordisk: the figures
| Figure | Boston Scientific | Novo Nordisk |
|---|---|---|
| Share price | $45.82 (November 4, 2026) | $42.18 (November 4, 2026) |
| Market cap | $66.4 billion | $186.0 billion |
| P/E (TTM) | 19.3x | 10.3x |
| Forward P/E | 14.6x | 1.8x |
| Revenue growth (quarter) | +1.4% | +2.1% |
| Net margin (TTM) | 16.6% | 35.3% |
| Net debt / EBITDA | 2.0x | 0.5x |
| Dividend yield | 0.00% | 4.47% |
| Beta | 0.58 | 0.37 |
Boston Scientific and Novo Nordisk figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Boston Scientific or Novo Nordisk figure is not available, and we never estimate it.
3 key differences between Boston Scientific and Novo Nordisk
- Valuation: Boston Scientific trades at 19.3x its annual earnings and Novo Nordisk at 10.3x; the market pays more for each dollar of Boston Scientific profit, usually because it expects more growth.
- Dividend: Novo Nordisk pays a dividend yielding 4.47% and Boston Scientific pays none.
- Profitability: for every 100 of sales, Novo Nordisk keeps 35.3 as net profit and Boston Scientific keeps 16.6.
Boston Scientific or Novo Nordisk: which fits your profile
- If you want growth: Novo Nordisk is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
- If you want income (dividends): Novo Nordisk pays the higher dividend relative to its price.
- If you prefer caution: Novo Nordisk has less debt relative to its profit, which usually gives more room in a bad year.
- If price is what matters most to you: Novo Nordisk trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.
Neither Boston Scientific nor Novo Nordisk wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
How Boston Scientific and Novo Nordisk make money
Boston Scientific (BSX)
Boston Scientific makes devices for minimally invasive procedures. Its Cardiovascular segment, the larger one, includes the Farapulse ablation system, the Watchman heart implant and stents, while MedSurg covers endoscopy, urology and neuromodulation products. Customers are hospitals and clinics across the United States, Europe and Asia. Full Boston Scientific analysis.
Novo Nordisk (NVO)
Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders. The United States is its biggest market, ahead of Europe, China and the rest of the world. Its ADRs trade in New York. Full Novo Nordisk analysis.
Frequently asked questions: Boston Scientific vs Novo Nordisk
Is Boston Scientific or Novo Nordisk the better stock?
Choosing between Boston Scientific and Novo Nordisk depends on what you are looking for. Novo Nordisk is growing faster right now, and Novo Nordisk trades on the lower P/E. Fintols does not tell you whether to buy Boston Scientific or Novo Nordisk: it shows you the differences so you can decide.
Which pays a higher dividend, Boston Scientific or Novo Nordisk?
As of November 4, 2026, Novo Nordisk yields 4.47% and Boston Scientific pays none. Also check how much of their profit Boston Scientific and Novo Nordisk pay out: if it is more than they earn, it cannot last.
Which is more expensive, Boston Scientific or Novo Nordisk?
On P/E, Boston Scientific (19.3x) is more expensive than Novo Nordisk (10.3x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.
Can I own both Boston Scientific and Novo Nordisk?
Yes. Many people spread their money across several companies, such as Boston Scientific and Novo Nordisk, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Boston Scientific or Novo Nordisk.
More comparisons with Boston Scientific or Novo Nordisk
- Boston Scientific vs Vertex
- Boston Scientific vs Stryker
- Novo Nordisk vs Vertex
- Novo Nordisk vs Stryker
More companies like Boston Scientific and Novo Nordisk: healthcare and pharma stocks. Educational content about Boston Scientific and Novo Nordisk, not investment advice.